# Asahi Kasei Pharma

> Asahi Kasei Pharma is a VC fund in Tokyo backing Biotechnology and Medical. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 5
- Last investment: Jan 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/旭化成ファーマ（株）
- Website: https://www.asahikasei-pharma.co.jp/en/

Asahi Kasei Pharma is a VC fund in Tokyo focused on Biotechnology and Medical. Asahi Kasei Pharma is growing as a specialty pharmaceutical firm with a global presence by focusing on the development of new world-class drugs in selected therapeutic fields. In diagnostics, management resources are concentrated on products with strong growth prospects.

## Contacts

5 contacts available for Asahi Kasei Pharma. Shizune tracks 1 team members at Asahi Kasei Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/asahi-kasei-pharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Medical | 3 | 60% |
| Health Care | 3 | 60% |
| Analytics | 1 | 20% |
| Therapeutics | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 2 | 40% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dalton Einhorn | Director New Pharma Ventures | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mediar Therapeutics | Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M | Series B | Jan 07, 2026 |  |
| Curreio | Curreio develops contract business for structural analysis using cryo-electron microscopy. |  | Series A | Mar 20, 2023 |  |
| LUCA Science | LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M | Series B | Jun 06, 2022 |  |
| Curreio | Curreio develops contract business for structural analysis using cryo-electron microscopy. |  | Series A | Jun 23, 2021 |  |
| Pulmocide | Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $92M | Series C | May 27, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 3 deals together
- Asahi Kasei Pharma — VC Fund, 2 deals together
- [Beyond Next Ventures](https://shizune.co/investors/profile/beyond-next-ventures) — VC Fund, 2 deals together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 2 deals together
- [Longwood Fund](https://shizune.co/investors/profile/longwood-founders-fund) — VC Fund, 2 deals together
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Asahi Kasei Pharma invest in?

Asahi Kasei Pharma invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Asahi Kasei Pharma?

Public channels for Asahi Kasei Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Asahi Kasei Pharma?

The team at Asahi Kasei Pharma includes Dalton Einhorn (Director New Pharma Ventures). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co